http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 04:41:52 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/BeOne+Medicines+%28ONC%29+Reiterated+at+Market+Outperform+by+Citizens+/26594421.html <p>Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $396.00 price target on BeOne Medicines (NASDAQ: ONC).</p><p>The analyst commented, " We reiterate our Market Outperform rating for BeOne Medicines and our price target of $396 based on a discounted EPS and revenue multiple analysis. BeOne’s ASCO 2026 solid tumor update provided the first clinical data package across three priority assets moving toward pivotal development: BGB-43395 in 1L HR+/HER2- mBC, BG-C9074 in OC maintenance, and BGB-B2033 in HCC. In our opinion, BeOne’s solid tumor strategy is moving from promise to clinical PoC to pivotal trials, with each asset addressing a http://www.streetinsider.com/Analyst+Comments/BeOne+Medicines+%28ONC%29+Reiterated+at+Market+Outperform+by+Citizens+/26594421.html Wed, 03 Jun 2026 04:41:52 -0400 ONC http://www.streetinsider.com/Analyst+PT+Change/BeOne+Medicines+%28ONC%29+PT+Raised+to+%24436+at+RBC+Capital/26587387.html (Updated - June 2, 2026 8:15 AM EDT) <p>RBC Capital analyst Leonid Timashev raised the price target on BeOne Medicines (NASDAQ: ONC) to $436.00 (from $425.00) while maintaining an Outperform rating.</p><p>The analyst commented: "Tidbits From ASCO Event: Solid Tumor Portfolio Shows Differentiating Characteristics, And Worth Valuing; On Monday, ONC presented on three interesting solid tumor assets - a CDk4 inhibitor in breast cancer, a GPC3-41BB bispecific in HCC, and a B7-H4 ADC in ovarian cancer. We think each looks to be delivering on its promised profile, with either unique safety or efficacy advantages, which can make them best-in-class, or at least http://www.streetinsider.com/Analyst+PT+Change/BeOne+Medicines+%28ONC%29+PT+Raised+to+%24436+at+RBC+Capital/26587387.html Tue, 02 Jun 2026 08:15:36 -0400 ONC http://www.streetinsider.com/Analyst+Comments/BeOne+Medicines+%28ONC%29+PT+Raised+to+%24436+at+RBC+Capital/26587387.html (Updated - June 2, 2026 8:15 AM EDT) <p>RBC Capital analyst Leonid Timashev raised the price target on BeOne Medicines (NASDAQ: ONC) to $436.00 (from $425.00) while maintaining an Outperform rating.</p><p>The analyst commented: "Tidbits From ASCO Event: Solid Tumor Portfolio Shows Differentiating Characteristics, And Worth Valuing; On Monday, ONC presented on three interesting solid tumor assets - a CDk4 inhibitor in breast cancer, a GPC3-41BB bispecific in HCC, and a B7-H4 ADC in ovarian cancer. We think each looks to be delivering on its promised profile, with either unique safety or efficacy advantages, which can make them best-in-class, or at least http://www.streetinsider.com/Analyst+Comments/BeOne+Medicines+%28ONC%29+PT+Raised+to+%24436+at+RBC+Capital/26587387.html Tue, 02 Jun 2026 08:15:36 -0400 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html <p class="bwalignc"> <i>Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy</i> </p><p class="bwalignc"> <i>BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLL</i> </p><p class="bwalignc"> <i>Data reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54543794&amp;newsitemid=20260529392296&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=e0d28ffb8b98b505a00b52194f114df9" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html Fri, 29 May 2026 06:00:00 -0400 06160 688235 A.06822034 A.30678504 A.31034861 A.31066700 A.50216726 O.07123365 O.16683936 O.20026344 O.21612337 O.22422661 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html <p class="bwalignc"> <i>Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy</i> </p><p class="bwalignc"> <i>BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLL</i> </p><p class="bwalignc"> <i>Data reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54543794&amp;newsitemid=20260529392296&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=e0d28ffb8b98b505a00b52194f114df9" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html Fri, 29 May 2026 06:00:00 -0400 06160 688235 A.06822034 A.30678504 A.31034861 A.31066700 A.50216726 O.07123365 O.16683936 O.20026344 O.21612337 O.22422661 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html <p class="bwalignc"> <i>Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy</i> </p><p class="bwalignc"> <i>BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLL</i> </p><p class="bwalignc"> <i>Data reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54543794&amp;newsitemid=20260529392296&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=e0d28ffb8b98b505a00b52194f114df9" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html Fri, 29 May 2026 06:00:00 -0400 06160 688235 A.06822034 A.30678504 A.31034861 A.31066700 A.50216726 O.07123365 O.16683936 O.20026344 O.21612337 O.22422661 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html <p class="bwalignc"> <i>Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy</i> </p><p class="bwalignc"> <i>BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLL</i> </p><p class="bwalignc"> <i>Data reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54543794&amp;newsitemid=20260529392296&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=e0d28ffb8b98b505a00b52194f114df9" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html Fri, 29 May 2026 06:00:00 -0400 06160 688235 A.06822034 A.30678504 A.31034861 A.31066700 A.50216726 O.07123365 O.16683936 O.20026344 O.21612337 O.22422661 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html <p class="bwalignc"> <i>Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy</i> </p><p class="bwalignc"> <i>BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLL</i> </p><p class="bwalignc"> <i>Data reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54543794&amp;newsitemid=20260529392296&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=e0d28ffb8b98b505a00b52194f114df9" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html Fri, 29 May 2026 06:00:00 -0400 06160 688235 A.06822034 A.30678504 A.31034861 A.31066700 A.50216726 O.07123365 O.16683936 O.20026344 O.21612337 O.22422661 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html <p class="bwalignc"> <i>Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy</i> </p><p class="bwalignc"> <i>BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLL</i> </p><p class="bwalignc"> <i>Data reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54543794&amp;newsitemid=20260529392296&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=e0d28ffb8b98b505a00b52194f114df9" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html Fri, 29 May 2026 06:00:00 -0400 06160 688235 A.06822034 A.30678504 A.31034861 A.31066700 A.50216726 O.07123365 O.16683936 O.20026344 O.21612337 O.22422661 O.76306903 ONC